10-K: Bioxytran Faces Going Concern Uncertainty Despite Efforts in Drug Development and Subsidiary Acquisition

Bioxytran's Form 10-K reveals ongoing losses and dependence on future financing for its drug development programs, including BXT-25 and ProLectin-Rx, despite recent subsidiary acquisition and IND approvals.

Summary

• Bioxytran, Inc., a clinical-stage pharmaceutical company, faces substantial doubt about its ability to continue as a going concern due to limited resources, operating history, and an accumulated deficit of $18.9 million as of December 31, 2024.
• The company is focused on developing BXT-25, an oxygen-carrying molecule for hypoxic conditions, and ProLectin-Rx, a galectin antagonist for viral diseases.
• Bioxytran acquired NDPD Pharma, Inc., in October 2024 to enhance its intellectual property portfolio related to ProLectin-Rx.
• The company's research and development expenses decreased significantly in 2024 due to a lack of funding, with expenses totaling $112,337 compared to $1.15 million in 2023.
• General and administrative expenses also decreased, primarily due to officers forfeiting a portion of their salaries.
• The company's net loss for 2024 was $2.37 million, a decrease from the $4.47 million loss in 2023.
• Bioxytran plans to raise additional capital through private placements to fund its operations and drug development programs.
• The company's management acknowledges material weaknesses in internal control over financial reporting, particularly regarding segregation of duties.
• The company's independent auditor, Fruci & Associates II, PLLC, has expressed an unqualified opinion on the financial statements but has also noted the going concern uncertainty.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a high degree of uncertainty regarding the company's future viability. While there are some positive developments, the overall tone is negative due to the going concern warning and material weaknesses in internal controls.

Positives

• The company's net loss decreased significantly in 2024 compared to 2023.
• Bioxytran successfully acquired NDPD Pharma, expanding its intellectual property portfolio.
• The company has IND approvals from both the FDA and CDSCO for ProLectin-M clinical trials.
• Management is actively seeking additional capital through private placements.

Negatives

• Bioxytran faces 'substantial doubt' about its ability to continue as a going concern.
• The company has a significant accumulated deficit of $18.9 million as of December 31, 2024.
• Research and development expenses decreased significantly due to funding constraints.
• The company acknowledges material weaknesses in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• Failure to obtain additional funding could force the company to curtail or cease operations.
• The company's drug development programs are subject to regulatory risks and clinical trial uncertainties.
• Material weaknesses in internal control over financial reporting could lead to material misstatements in the company's financial statements.
• The company's reliance on a small management team presents a risk if key personnel are lost.

Future Outlook

The company plans to raise additional capital through private placements to fund its operations and drug development programs, but there is no assurance that these funds will be available on acceptable terms or at all.

Industry Context

The company operates in the competitive pharmaceutical industry, focusing on novel therapeutic opportunities in hypoxia and viral diseases. The company's success depends on its ability to develop and commercialize its drug candidates, navigate regulatory hurdles, and secure adequate funding.

Comparison to Industry Standards

• It is difficult to compare Bioxytran's results to industry standards due to its early stage of development and lack of revenue.
• Comparable companies in the clinical-stage pharmaceutical industry often face similar challenges related to funding, regulatory approvals, and clinical trial outcomes.
• Many companies in the pharmaceutical industry are developing oxygen therapeutics for perfusion and oxygenation of ischemic tissue; none have yet succeeded in becoming a proven oxygen therapeutics for stroke and wound healing.

Related Party Transactions

• The company acquired NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Company's officers.
• The company has a License Agreement for a medical device with an affiliated company where in the Company's Officers hold a majority interest.
• There were $147,286 in Accounts Payables to related parties in form of payroll and advanced expense, there was also a short-term loan from affiliates of $241,078 with $6,950 in accrued interest.

Stakeholder Impact

• Shareholders face significant risk of dilution and loss of investment due to the company's need for additional financing and the potential for conversion of convertible notes.
• Employees face uncertainty regarding job security due to the company's financial instability.
• The company's ability to develop and commercialize its drug candidates is critical for patients who may benefit from these therapies.

Next Steps

• The company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as funding permits.
• The company intends to issue a Private Placement Offering under Regulation D in the order of $4 million in the spring of 2025.
• The trial is planned to restart start on, or around, May 1, 2025.
• The trial is expected to start in the second quarter of 2025, provided we obtain adequate funding.

Key Dates

Keywords

Bioxytran, BXT-25, ProLectin-Rx, NDPD Pharma, Hypoxia, Pharmaceutical, Clinical Stage, Going Concern, Financial Results, Drug Development, Stock Plan, Convertible Notes, Acquisition, FDA, CDSCO